Seo Salimi

Domestic Representations

Aktis Oncology in its $350 million initial public offering.
Karuna Therapeutics in its initial public offering and follow-on offerings, aggregating over $1.5 billion in proceeds.
HOOKIPA Pharma in its initial public offering and follow-on offerings, aggregating over $200 million in proceeds.
Goldman Sachs & Co. and other underwriters in the initial public offering and follow-on offerings by Arvinas, aggregating over $600 million in proceeds.
Goldman Sachs & Co. and other underwriters in the $145 million initial public offering by Omega Therapeutics.
Goldman Sachs & Co. and the other underwriters in the $145 million initial offering by Harmony Biosciences Holdings.
Goldman Sachs & Co. and Morgan Stanley and other underwriters in the $135 million initial public offering by Pandion Therapeutics.
Goldman Sachs & Co. and J.P. Morgan as underwriters in over $1.5 billion of equity offerings by Sarepta Therapeutics.
Goldman Sachs & Co. and other underwriters in follow-on public offerings by Syndax Pharmaceuticals, aggregating over $500 million in proceeds.
BofA Securities and Goldman Sachs & Co. in the $350 million PIPE financing by Arvinas.
J.P. Morgan Securities and other underwriters in the initial public offering and subsequent PIPE financing by Lexeo Therapeutics aggregating over $200 million.
J.P. Morgan Securities and other underwriters in the $100 million follow-on offering by Vor Biopharma.
TD Cowen in the $150 million PIPE financing by Harpoon Therapeutics.
Jefferies in the $90 million follow on-offering by Esperion Therapeutics.
Piper Sandler and Raymond James in the $260 million follow-on offering by CymaBay Therapeutics.